Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study

Overview

Journal Integr Pharm Res Pract

Date 2020 Oct 29

PMID 33117667

Citations 4

Authors

Merhawi Bahta

Tzeggai Berhe

Mulugeta Russom

Eyasu H Tesfamariam

Azieb Ogbaghebriel

Affiliations

Soon will be listed here.

Abstract

Background: ADRs to antipsychotics are amongst the major challenges in the treatment of patients with psychotic disorders. The extent of patient-reported ADRs assessed in many studies using standardized scales is found to be inconsistent. However, there is a paucity of such research in Eritrea. The aim of the study is therefore to determine the magnitude, nature, and the possible risk factors associated with ADRs of the first generation antipsychotics in outpatients with schizophrenia at Saint Mary Neuro-Psychiatric National Referral Hospital in Asmara, Eritrea, using the LUNSERS self-rating scale.

Methods: A cross-sectional, descriptive and analytical study design utilizing a quantitative approach was employed. Data were collected from patients' self-administered questionnaires, interviews, and medical records. The collected variables were analyzed using SPSS 22.0 with descriptive statistics, correlation, t-tests, ANOVA, and multiple regression. Statistical significance was tested at -value<0.05.

Results: In this study, 93.8% of the research participants experienced at least one ADR. LUNSERS total mean score of the relevant items was 28.01 (SD=18.46) with 24.7% of the study participants scoring medium-to-high. The prevalence of the categories of ADRs was psychic (91.3%), autonomic (78.1%), extra-pyramidal (76.9%), miscellaneous (66.5%), hormonal (58.3%), anti-cholinergic (44.2%), and allergic reactions (44.2%). At multivariate level, factors significantly and positively associated with total ADR score were smoking (=0.028) and being at secondary educational level (=0.015).

Conclusion: There was high prevalence of ADRs with moderate-to-high overall ADR scores in a significant number of patients. The most frequently reported ADRs were psychic, autonomic, extra-pyramidal, hormonal, and miscellaneous. Smoking and secondary level of education were found to be the main determinants of ADRs.

Citing Articles

Variation of adverse drug events in different settings in Africa: a systematic review.

Nyame L, Hu Y, Xue H, Fiagbey E, Li X, Tian Y Eur J Med Res. 2024; 29(1):333.

PMID: 38880895 PMC: 11181533. DOI: 10.1186/s40001-024-01934-0.

Best practices for documentation of psychotropic drug-drug interactions in an adult psychiatric clinic.

Collins K, Dopheide J, Wang M, Keshishian T Ment Health Clin. 2023; 13(1):11-17.

PMID: 36891479 PMC: 9987259. DOI: 10.9740/mhc.2023.02.011.

Adverse Drug Reaction and Its Predictors Among Psychiatric Patients Taking Psychotropic Medications at the Mizan-Tepi University Teaching Hospital.

Ejeta F, Aferu T, Feyisa D, Kebede O, Siraj J, Hammeso W Neuropsychiatr Dis Treat. 2022; 17:3827-3835.

PMID: 35002242 PMC: 8721157. DOI: 10.2147/NDT.S349127.

Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study.

Bahta M, Ogbaghebriel A, Russom M, Tesfamariam E, Berhe T Ann Gen Psychiatry. 2021; 20(1):27.

PMID: 33894789 PMC: 8070289. DOI: 10.1186/s12991-021-00348-0.

References

Chiang Y, Klainin-Yobas P, Ignacio J, Chng C . The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nurs. 2011; 20(15-16):2172-82. DOI: 10.1111/j.1365-2702.2010.03659.x. View

Bollini P, Pampallona S, Orza M, Adams M, CHALMERS T . Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med. 1994; 24(2):307-16. DOI: 10.1017/s003329170002729x. View

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-62. DOI: 10.1016/S0140-6736(13)60733-3. View

Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004; 5(1):6-13. DOI: 10.1038/sj.tpj.6500285. View

Dudley K, Liu X, De Haan S . Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev. 2017; 4:CD007778. PMC: 6478116. DOI: 10.1002/14651858.CD007778.pub2. View

Kahn R, Sommer I, Murray R, Meyer-Lindenberg A, Weinberger D, Cannon T . Schizophrenia. Nat Rev Dis Primers. 2016; 1:15067. DOI: 10.1038/nrdp.2015.67. View

Marder S . Monitoring treatment and managing adherence in schizophrenia. J Clin Psychiatry. 2013; 74(10):e21. DOI: 10.4088/JCP.12117tx2c. View

Morrison P, Gaskill D, Meehan T, Lunney P, Lawrence G, Collings P . The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Aust N Z J Ment Health Nurs. 2002; 9(4):166-76. DOI: 10.1046/j.1440-0979.2000.00181.x. View

Pakpoor J, Agius M . A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatr Danub. 2014; 26 Suppl 1:273-84. View

10.

DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E . A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12:20. PMC: 3342101. DOI: 10.1186/1471-244X-12-20. View

11.

Peluso M, Lewis S, Barnes T, Jones P . Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012; 200(5):387-92. DOI: 10.1192/bjp.bp.111.101485. View

12.

Young S, Taylor M, Lawrie S . "First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2014; 29(4):353-62. DOI: 10.1177/0269881114562090. View

13.

Morrison P, Meehan T, Stomski N . Australian case managers' views about the impact of antipsychotic medication on mental health consumers. Int J Ment Health Nurs. 2015; 24(6):547-53. DOI: 10.1111/inm.12154. View

14.

Haro J, Novick D, Perrin E, Bertsch J, Knapp M . Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship?. Psychiatry Res. 2014; 220(1-2):163-9. DOI: 10.1016/j.psychres.2014.07.034. View

15.

Day J, Wood G, Dewey M, Bentall R . A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995; 166(5):650-3. DOI: 10.1192/bjp.166.5.650. View

16.

Day J, Kinderman P, Bentall R . A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998; 97(1):93-7. DOI: 10.1111/j.1600-0447.1998.tb09969.x. View

17.

Kreyenbuhl J, Buchanan R, Dickerson F, Dixon L . The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2009; 36(1):94-103. PMC: 2800150. DOI: 10.1093/schbul/sbp130. View

18.

Sweileh W, Odeh J, Shraim N, Zyoud S, Sawalha A, Al-Jabi S . Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm J. 2014; 22(2):127-32. PMC: 3950502. DOI: 10.1016/j.jsps.2013.03.003. View

19.

Kobylecki C, Jakobsen K, Hansen T, Jakobsen I, Rasmussen H, Werge T . CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology. 2009; 59(4):222-6. DOI: 10.1159/000223734. View

20.

Waterreus A, Morgan V, Castle D, Galletly C, Jablensky A, Di Prinzio P . Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012; 46(8):762-73. DOI: 10.1177/0004867412450471. View